Sugi Predict

Sugi Predict / Compounds / SCHEMBL162911

SCHEMBL162911

SCHEMBL162911

FC(F)(F)c1cccnc1Br

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 1/20 0.43
▸ TRIM24 O15164 1/20 0.42
▸ TRIM33 Q9UPN9 1/20 0.42
▸ HSD11B1 P28845 6/20 0.41
▸ NFE2L2 Q16236 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ TNF P01375 1/20 0.37
▸ CXCL8 P10145 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ PAX8 Q06710 1/20 0.37
▸ KLF5 Q13887 1/20 0.37
▸ AXL P30530 1/20 0.37
▸ TAAR1 Q96RJ0 1/20 0.37
▸ CTNNB1 P35222 1/20 0.37
▸ WNT3A P56704 1/20 0.37
▸ LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29369617 1.00 EPHX2 (0.43) EPHX2TRIM24TRIM33HSD11B1NFE2L2
SCHEMBL321342 0.81 TRIM24 (0.45) EPHX2TRIM24TRIM33MEN1KMT2A
SCHEMBL26599140 0.78 TRIM24 (0.36) EPHX2TRIM24TRIM33HSD11B1MEN1
SCHEMBL2608421 0.77 TRIM24 (0.42) TRIM24TRIM33KMT2ALMNA
SCHEMBL8778858 0.77 TRIM24 (0.42) TRIM24TRIM33AXLLMNA
SCHEMBL15624412 0.76 TRPV1 (0.47) EPHX2
SCHEMBL4705535 0.75 ACP3 (0.38) EPHX2HSD11B1MEN1TNFCXCL8
SCHEMBL4707042 0.75 CNR2 (0.52) HSD11B1CTNNB1WNT3ALMNA
SCHEMBL31608519 0.74 EPHX2 (0.44) EPHX2HSD11B1NFE2L2MEN1TNF
SCHEMBL610024 0.74 EPHX2 (0.44) EPHX2HSD11B1NFE2L2MEN1TNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 425 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-56115776-A — — None — — JP disclosed
US-20260109671-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS INC (US) 2026-04-23 — — US disclosed
EP-3558298-B1 ANTIDIABETIC SPIROCHROMAN COMPOUNDS MERCK SHARP & DOHME LLC (US) 2026-03-11 — — EP disclosed
US-12454547-B2 Steroidal compositions and methods of treating lipogenic cancers Asteroid Therapeutics (US) 2025-10-28 — — US disclosed
US-12448352-B2 Beta adrenergic agonist and methods of using the same CURASEN THERAPEUTICS, INC. (US) 2025-10-21 — — US disclosed
US-20250230172-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF VANQUA BIO, INC. (US) 2025-07-17 — — US disclosed
EP-4552697-A2 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE Novartis AG (CH) 2025-05-14 — — EP disclosed
EP-3514151-B1 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2025-04-23 — — EP disclosed
WO-2025072539-A1 AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF PLIANT THERAPEUTICS, INC. (US) 2025-04-03 — — WO disclosed
CN-119638780-A Nitrogen-containing compound, preparation method and application thereof 成都地奥制药集团有限公司 2025-03-18 — — CN disclosed
US-20020120011-A1 Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity SIKORSKI JAMES A (US) 2002-08-29 — — US disclosed
WO-2002049648-A1 HETEROARYL UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS SCHERING CORPORATION (US) 2002-06-27 — — WO disclosed
EP-1121357-A1 2-HETARYL-3,4-DIHYDRO-2H-PYRROLE DERIVATIVES Bayer Aktiengesellschaft (DE) 2001-08-08 — — EP disclosed
EP-1115693-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY Monsanto Company (US) 2001-07-18 — — EP disclosed
EP-1070052-A1 FUNGICIDE COMPOSITIONS COMPRISING A HYDROXIMIC OR HYDRAZONIC GROUP AVENTIS CROPSCIENCE S.A. (FR) 2001-01-24 — — EP disclosed
EP-1052252-A1 Diaminobenzene derivatives and dyeing preparations containing them Wella Aktiengesellschaft (DE) 2000-11-15 — — EP disclosed
WO-2000021958-A1 2-HETARYL-3,4-DIHYDRO-2H-PYRROLE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2000-04-20 — — WO disclosed
WO-2000018721-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY MONSANTO COMPANY (US) 2000-04-06 — — WO disclosed
WO-1999051579-A1 FUNGICIDE COMPOSITIONS COMPRISING A HYDROXIMIC OR HYDRAZONIC GROUP AVENTIS CROPSCIENCE S.A. (FR) 1999-10-14 — — WO disclosed
JP-S56115776-A PREPARATION OF 2-BROMO-TRIFLUOROMETHYLPYRIDINE ISHIHARA SANGYO KAISHA LTD 1981-09-11 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12454547-B2 Steroidal compositions and methods of treating lipogenic cancers SREBF1, SREBF2, NR1H3 EPHX2 703/4885TRIM24 2305/4885TRIM33 3199/4885
US-12448352-B2 Beta adrenergic agonist and methods of using the same ADRA2B, ADRB2, ADRB1 EPHX2 1864/4885TRIM24 4391/4885TRIM33 2699/4885
US-20020120011-A1 Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity CETP, PCTP, DBI EPHX2 2049/4885TRIM24 1617/4885TRIM33 2515/4885
US-20260109671-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME ADRB2, ADRB1, ADRA2C EPHX2 1814/4885TRIM24 4134/4885TRIM33 3748/4885
US-20250230172-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF GBA1, GAA, GBA2 EPHX2 2639/4885TRIM24 3538/4885TRIM33 4466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.